Physician

Jason David Taksey, M.D.

According to 2025 Medicare claims, Jason Taksey, M.D. (NPI: 1316017676) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Anne Arundel, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21401-9998. Taksey is affiliated with the Aledade 61 WA CCCN CHC MSSP Enhanced (ACO ID: A4777), participating under the MSSP model.

Taksey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 983 traditional Medicare patients, billed 336,936 HCPCS/CPT codes, and received $7,324,325 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,515 prescription claims across 299 beneficiaries totaling $6,446,750 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 48 claims. Open Payments data shows 31 records totaling $31,019. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $127,316 to $7,324,325. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,522,625 to $6,446,750. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,633 to $5,397.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	609	2,002	$127,316
2016	628	1,981	$124,512
2017	645	1,888	$126,506
2018	726	23,325	$767,959
2019	762	32,015	$1,017,284
2020	804	71,632	$2,112,512
2021	704	235,813	$4,882,860
2022	782	306,809	$5,653,092
2023	823	262,182	$5,161,620
2024	983	336,936	$7,324,325

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	170	1,437	$1,522,625
2016	182	1,327	$1,413,530
2017	171	1,210	$1,330,493
2018	180	1,452	$2,568,075
2019	206	1,596	$2,852,248
2020	222	1,710	$3,662,174
2021	213	1,922	$4,004,672
2022	236	2,006	$3,686,882
2023	234	2,039	$4,785,802
2024	299	2,515	$6,446,750

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	102	$24,762
2016	N/R	24	$1,012
2017	14	111	$22,560
2018	11	153	$14,589
2019	N/R	13	$245
2020	N/R	42	$2,683
2021	N/R	130	$8,202
2022	N/R	68	$2,716
2023	N/R	N/R	N/R
2024	N/R	48	$1,066

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	192	894	$106
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	484	969	$99
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	332	507	$71
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	360	462	$13
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	563	2,630	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	90	2,457	$1,183,280
Nubeqa	Darolutamide	42	1,440	$605,211
Pomalyst	Pomalidomide	21	588	$500,261
Brukinsa	Zanubrutinib	33	990	$367,673
Xtandi	Enzalutamide	24	898	$347,496

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$436
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	23	$395
K0003	Lightweight wheelchair	Y	N/R	12	$235

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$819	Intera Oncology, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$30,200	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jason David Taksey, M.D.?

Tedicare shows public-source Medicare data for Jason David Taksey, M.D. (NPI 1316017676), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jason David Taksey, M.D. have ACO affiliation data?

Jason David Taksey, M.D. is shown with ACO affiliation data for Aledade 61 WA CCCN CHC MSSP Enhanced (MSSP, ACO ID A4777).

What billing organization is linked to Jason David Taksey, M.D.?

Jason David Taksey, M.D. is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Jason David Taksey, M.D. have Open Payments data?

Jason David Taksey, M.D. has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.